📈 Economy
Hit
✦ AI
The ISM Services PMI for June 2026 came in at 54.0, matching consensus and firmly in expansion territory. The US services sector has been in uninterrupted expansion for 12+ months. Sub-indices: Business Activity 55.4%, New Orders 55.1%, Employment 51.2%. Even a sharp July pullback would be unlikely to breach the 50 threshold. No Polymarket anchor; historical Services PMI stability above 50 is well-established. Note: this is the Services PMI — the ISM Manufacturing PMI for July is already separately forecast.
🍾 Beverages
Hit
✦ AI
CCH achieved +11.6% organic revenue growth in Q1 2026 (volume +9.6%), well above its full-year guidance of 6–7%. The company reaffirmed this outlook in May 2026 despite macro headwinds. Key growth drivers include the Africa segment and the energy drinks portfolio (Monster, Predator). A hot European summer further supports H1 beverage volumes. CCH will publish H1 2026 results on 5 August 2026 at 07:00 BST. No Polymarket quote available.
📈 Economy
Hit
✦ AI
Eli Lilly reports on August 5, 2026 before market open. The company is the global market leader in the GLP-1 segment (Mounjaro/Zepbound). Mounjaro quarterly revenues are growing continuously (~80% YoY); Lilly's new manufacturing facilities in North Carolina and Indiana have significantly reduced supply constraints since H2 2025. Lilly has beaten EPS consensus for five consecutive quarters and raised annual guidance four times. The Zepbound approval portfolio (obesity, heart failure) continues to expand. No Polymarket market; own estimate 79% based on structurally strong GLP-1 growth trajectory.
📈 Economy
Miss
✦ AI
Eli Lilly reports Q2 2026 on August 5. Consensus stands at $8.81–8.85 adjusted EPS per TipRanks. In Q1 2026, Lilly beat by a remarkable 24.8% ($8.55 vs. $6.85 expected), driven by strong tirzepatide (Mounjaro/Zepbound) volumes and sustained GLP-1 demand. Manufacturing capacity was massively expanded in 2025–2026. Risks: US healthcare pricing pressure, potential rebate negotiations. Beat probability: 76%, as consensus estimates after a large Q1 beat tend to lag full ramp-up.
📈 Economy
Hit
✦ AI
ISM Services PMI data for July 2026 will be released on August 5. In June 2026 the index stood at 54.0, in May 2026 at 54.5 — keeping the US services sector solidly in expansion territory for months. The 53.0 threshold is significantly below recent readings; a drop below 53 would require an acceleration of the decline of more than 2 index points vs June. Headwinds from softening private consumption and elevated rates (currently 3.50–3.75%) are to be factored in, but insufficient to push below 53. No Polymarket/Kalshi price available; trend extrapolation based on 6-month baseline.
📈 Economy
Miss
✦ AI
Eli Lilly reports on August 5, 2026. The EPS consensus per Hudson Labs is ~$8.89 adjusted Non-GAAP EPS. Eli Lilly has beaten estimates for eight consecutive quarters, driven by explosive growth of Mounjaro (tirzepatide, diabetes/GLP-1) and Zepbound (obesity). The GLP-1 segment grows double-digits and routinely outpaces analyst estimates. No Polymarket market available; assessment based on ~85–90% historical beat rate over the last 8 quarters. Risk: potential supply constraints or price pressure from IRA negotiations.
🍾 Beverages
Hit
✦ AI
Primo Brands (Thermos, ReadyRefresh, Mountain Valley) reported Q1 2026 net revenues of $1.63B, above analyst estimates. Q2 is peak season for bottled water in North America (summer). The $1.60B threshold is 1.8% below Q1 – a conservative bar. 19 analysts cover the stock; average price target $27.91 (+20%). No prediction market; own estimate 72%.
📈 Economy
Hit
✦ AI
Novo Nordisk reports H1-2026 results on August 5 at 07:30 CEST. EPS consensus is $5.31; revenue consensus ~DKK 73.06B (Unusual Whales/MarketBeat, July 2026). Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 1.0/2.0 mg) dominate the globally growing GLP-1 market. Novo has beaten EPS consensus in more than six consecutive quarters. Risks: US IRA negotiations on GLP-1 reimbursement, competition from Eli Lilly's tirzepatide, China price pressure. No specific prediction market.
📈 Economy
Hit
✦ AI
Novo Nordisk reports Q2 2026 on August 5. The ADS EPS consensus stands at approximately $0.82 per TipRanks. GLP-1 demand for semaglutide (Ozempic/Wegovy) remains structurally strong; Novo benefits from global capacity expansion and growing reimbursements in Europe and the US. Competitive pressure from Eli Lilly (tirzepatide) is priced in. Novo has beaten EPS consensus in each of the last four quarters. Beat probability: 71%. Currency risk (DKK/USD, EUR/USD) could dampen USD ADS translation. No Polymarket market available.
🍾 Beverages
Hit
✦ AI
Heineken reported organic net revenue growth of +2.8% in its Q1 2026 trading update (23 April 2026), driven by premium volume (+5.8%), the Heineken® brand (+6.9%) and global brands (+5.7%). The company confirmed its full-year guidance of 2–6% organic operating profit growth. H1 growth above 1.5% would be achievable even if Q2 drops to 0%. Headwinds: elevated input costs (aluminium, barley), purchasing-power softness in Sub-Saharan Africa, and subdued Middle East consumer demand due to the Hormuz conflict. The premium and no/low-alcohol segments support margins. No direct prediction market; basis is Q1 figures and company guidance.
💻 Technology
Miss
✦ AI
Uber's Mobility and Delivery segments are growing strongly, supported by Autonomous Vehicle partnerships (Waymo in San Francisco and Los Angeles). Management guided non-GAAP EPS of $0.78–$0.82; consensus sits at $0.84, already above the guidance range. Uber has beaten the EPS consensus in each of the past five quarters (100% beat rate). No Polymarket quote; calibrated on historical beat pattern and trip-volume growth.
🍾 Beverages
Hit
✦ AI
Dutch Bros targets full-year 2026 revenues of $2.0–$2.03B, implying a quarterly average of ~$500–$508M. Q2 is seasonally strong (summer beverages, aggressive expansion to >1,000 US locations). The $490M threshold is slightly below the quarterly average. Q1 2026 EPS beat estimates. Analyst consensus: Strong Buy. No prediction market; own estimate 68%.
📈 Economy
Miss
✦ AI
Uber guided Q2 2026 Non-GAAP EPS of $0.78–$0.82 per share. The analyst consensus at ~$0.84 is materially above the midpoint of Uber's own guidance – a recurring pattern that often leads to beats. Uber posted strong Q1 2026 results; Q2 Gross Bookings guidance is $56.25–57.75 billion. Key drivers: continued mobility growth in North America and Asia, plus Delivery expansion. Uber consistently beats when guiding conservatively. No Polymarket quote for Uber EPS; own estimate: ~65%.
📈 Economy
Hit
✦ AI
Disney+ and Hulu have been profitable since Q2 FY2025 and continue growing. The ESPN direct-to-consumer service (launched autumn 2025) expands the subscription portfolio. The Parks segment is recovering from earlier hurricane headwinds. The consensus of $1.88 per share (+16.8% YoY) looks conservative: Disney's historical beat rate over the last six quarters is approximately 80%. No Polymarket quote; calibrated on streaming momentum and operational improvement trends.
📈 Economy
Miss
✦ AI
Eli Lilly reports Q2 2026 on August 5 before market open. EPS consensus is approx. $8.89/share (Meyka/TipRanks); revenue consensus is $20.5B. Structural driver: GLP-1 demand for Mounjaro (diabetes) and Zepbound (obesity) remains relentless; Lilly is market leader in the fast-growing incretin segment. Lilly has consistently beaten estimates in recent quarters. Risk factors: incretin production capacity constraints; potential US drug pricing pressure (IRA implementation). No Polymarket odds found; beat probability structurally high.
🍾 Beverages
Hit
✦ AI
Campari reported Q1 2026 (6 May 2026) organic growth of +2.9% — broad-based across 18 growth markets with strength across all brand houses (Campari, Aperol, Grand Marnier, Espolòn). Full-year guidance of ~3% organic growth (in line with 2025 pace) was reiterated. Falling below 2.5% in H1 would require a substantial Q2 deterioration vs. Q1. H1 results are typically published late July/early August. No Polymarket market available; own estimate ~60%.
💻 Technology
Miss
✦ AI
After months of tug-of-war between industry lobbyists and consumer advocates, the revised AI Liability Directive comes to a vote. Political pressure following several high-profile AI failures in EU member states has accelerated the timeline.
🍾 Beverages
Miss
✦ AI
Premium spirits industry suffers in 2025/26 from post-COVID normalisation, saturated trade inventories, and consumer caution in core US and European markets. LVMH Wines & Spirits confirmed an organic revenue decline for H1 2026 on 27 July 2026. Pernod Ricard and Diageo also have open predictions for organic declines. Campari H1 2025: +3.4% organic growth; Q1 2026 under pressure. Campari exposure: Aperol category (aperitif saturation), US bourbon (Wild Turkey). No official reporting date announced; historically late July/early August.
🍾 Beverages
Miss
✦ AI
Campari suffers from Aperol saturation in Western Europe, ongoing US retail destocking and US import tariffs on European products (10% surcharge since February 2026). H1 2025 already showed –4.2% organic net sales. Analyst consensus expects continued weakness in H1 2026. No Polymarket market; independent estimate based on IWSR industry trend and tariff headwinds.
🍾 Beverages
Miss
✦ AI
Heineken releases H1 results on August 5, 2026 at 07:00 CET. Q1 2026 showed +2.8% net revenue (+3.0% NR/hl), premium volumes +5.8% (Heineken® +6.9%), global brands +5.7%. FY2026 guidance: operating profit organic +2–6%. Q2 benefits seasonally from FIFA World Cup (Heineken is official WC beer partner), beer garden season, and European festivals. Achieving >3% organic net revenue growth requires slight acceleration vs Q1; EM currency risks weigh. No Polymarket/Kalshi quote available.
🍾 Beverages
Miss
✦ AI
Heineken reported organic net revenue growth of +2.8% in Q1 2026 (Trading Update, 23 April 2026). Full-year 2026 analyst consensus expects ~3.0–3.5% organic; FY guidance is +2 to +6% operating profit. H1 growth of >3% requires an acceleration vs Q1 – possible via (1) stronger premiumisation momentum in summer (Heineken 0.0, Amstel Ultra), (2) volume growth in Asia/Africa, (3) price increases from early 2026 with full Q2 effect. Headwinds: European consumer slowdown (PMI <50 platform prediction), FX headwinds. No Polymarket market; probability 50% – at the inflection point between Q1 disappointment and acceleration potential.
📈 Economy
Miss
✦ AI
Turkish annual inflation peaked above 85% in October 2022 and has fallen sharply on orthodox monetary policy (rate hiking cycle from May 2023, policy rate >40%) — reaching approximately 44% by December 2024. The disinflation trend continued through 2025; analysts estimate Turkish inflation at 20–35% for mid-2026 depending on trajectory. Breaking below 25% for July 2026 hinges critically on wage growth dynamics, energy imports (Brent at USD 87 weighs on TRY-denominated import costs) and the exchange-rate path. Risk: the elevated oil price may slow disinflation and delay the sub-25% crossing to Q4 2026. No Polymarket signal available. Assessment: 40% probability — ambitious but achievable threshold within the ongoing disinflation cycle.